EMA Authorised: Ranivisio (ranibizumab) — Midas Pharma GmbH

View source ↗

Summary

The EMA authorised Ranivisio (ranibizumab) for ocular indications including wet age-related macular degeneration, macular edema, and diabetic retinopathy, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy
• Wet Age-related Macular Degeneration

Drugs mentioned

• Ranivisio (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications. MAH: Midas Pharma GmbH. Decision date: 13/11/2025